Lifecore Biomedical (LFCR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Lifecore Biomedical (LFCR) is projected to report a Q1 loss of $0.30 per share, an improvement of 43.4% year-over-year, with revenues expected to rise 8% to $26.68 million for the quarter ended August 2025. Despite a 21.43% upward revision in consensus EPS estimates over the past month, the company's Zacks Earnings ESP of -3.33% and a Zacks Rank #3 indicate recent bearish analyst sentiment, suggesting a low probability of an earnings beat, especially considering its history of missing consensus in three of the last four quarters.

Analysis

Lifecore Biomedical (LFCR) is approaching its Q1 earnings with conflicting signals. The consensus outlook projects a year-over-year improvement, with an 8% rise in revenues to $26.68 million and a 43.4% reduction in the net loss to $0.30 per share. Supporting a positive view, the consensus EPS estimate has been revised 21.43% higher over the last 30 days, indicating a generally improved assessment from analysts during that period. However, more recent indicators suggest caution. The company's Zacks Earnings ESP is negative at -3.33%, revealing that the most recent analyst estimates have turned more bearish and are now below the consensus. This negative ESP, combined with a poor historical record of having missed EPS estimates in three of the last four quarters, makes an earnings beat appear unlikely. While the stock's Zacks Rank #3 (Hold) is neutral, the combination of negative recent sentiment and past underperformance casts doubt on the company's ability to meet expectations.

Key Decisions for Investors

• Given the negative Earnings ESP of -3.33% and a history of missing consensus, investors should consider trimming or hedging long positions to mitigate the risk of a post-earnings price decline.
• Pay close attention to the 8% projected revenue growth and management's forward-looking guidance on the earnings call, as strength in these areas could offset a potential EPS miss and support the stock.
• Despite the broader 30-day upward revision in EPS estimates, the more recent bearish turn suggested by the ESP and the stock's neutral 'Hold' rank warrant a cautious 'wait-and-see' approach until after the results are released before making new capital commitments.